Mifamurtide is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with post-operative multi-agent chemotherapy. Safety and efficacy have been assessed in studies of patients 2 to 30 years of age at initial diagnosis.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
2 - 2 mg per m² of body surface area (BSA)
From 2 To 2 mg per m² of body surface area (BSA) once every 3 day(s)
The recommended dose of mifamurtide for all patients is 2 mg/m² body surface area. It should be administered as adjuvant therapy following resection: twice weekly at least 3 days apart for 12 weeks, followed by once-weekly treatments for an additional 24 weeks for a total of 48 infusions in 36 weeks.
It is administered by intravenous infusion over a period of 1 hour.